Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL

Julia Jane Scarisbrick • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Bexarotene Brentuximab vedotin Methotrexate
ALCANZA

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, talks on the findings of the randomized Phase III ALCANZA trial (NCT01578499) of brentuximab vedotin versus physician’s choice of methotrexate or bexarotene in patients with CD30+ cutaneous T-cell lymphoma (CTCL). Prof. Scarisbrick reports that 120 patients were enrolled. The overall response rate and progression-free survival was found to be significantly higher amongst patients receiving brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Julia Jane Scarisbrick

0:59
PROCLIPI: identification of key prognostic factors in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:59
MAVORIC: mogamulizumab improves PFS for CTCL
Julia Jane Scarisbrick • 15 Oct 2021
1:10
The role of transplant in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:53
Maintenance therapy in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals